EPHB2 and cancer: Moreover, studies performed in different cancer cell lines showed that apigenin is able to inhibit FAK expression [178], FAK/Src activation, which affected motility and cytoskeleton remodeling (25 μM) [179], to block NNK-induced FAK phosphorylation and ERK activation, resulting in an overall lower proliferation and migration (50 μM) [180], and to inhibit the ERK-FAK pathway leading to a repression of the cells’ migratory ability [156].